


Ashley Berthelot


Professional Arts Pharmacy Lafayette, Louisiana
















Dave Miller

Keystone Pharmacy Grand Rapids, Michigan



Tenille Davis

Civic Center Compounding Scottsdale, Arizona



FELLOW

FELLOW of the ALLIANCE OF PHARMACY COMPOUNDING





Edward DeCaria RPh, FAPC



Patricia Douglas RPh, FAPC



Lisa Everett Andersen RPh, FAPC



Cheri Garvin RPh, FAPC



Shawn Hodges PharmD, FAPC



Jim Hrncir RPh, FAPC



Masoud Rashidi PharmD, FAPC



Nicolas Ruiz CPhT, FAPC



Doug Yoch PharmD, FAPC



The Pharmacy Compounding Professional's

lode of Ethics

Responsibilities to One's Patients, Self, Colleagues, and Profession

As a pharmacy compounding professional, I will:

- 1. Uphold the triad relationship patient, prescriber and pharmacist as the foundation of pharmacy practice, acting in patients' best interest by collaborating with patients, their caregivers, and other healthcare professionals to manage a patient's treatment.
 - Comply with all applicable state and federal laws and regulations.
- 3. Practice the art and science of pharmacy compounding with competence and integrity, assuring patient safety and the quality of compounds, maintaining accurate records, and utilizing the proper compounding facilities, equipment, and materials in compounding for
- 4. Recognize the limits of my own expertise, practice only if I am fit and competent to do so and refer to colleagues on issues beyond my knowledge and skill. to week by keeping my knowledge and skills up to
























Class of 2023






Threading the Regulatory Needle



Compounding the Joy of Living





Gail Bormel

Director, FDA Office of Compounding Quality & Compliance




Scott Brunner

CEO, Alliance for Pharmacy Compounding
















Tenille Davis


Civic Center Compounding Scottsdale, Arizona





Alexander Pytlarz

Infuserve America St. Petersburg, Florida



Scott Brunner
APC





Alliance for Pharmacy Compounding

Compounding the Joy of Living

APC Membership Meeting

The State of the Alliance • September 19, 2023



Financial Snapshot*



Income Sources: Membership 31% • CE & Conferences 18% • CPs 17% • OneFund 15% Primary Expenses: Staffing 58% • Advocacy 14% • Conferences 8% • Operations 19%

2021 YE

- Total Income: \$1,305,563
- Total Expense: \$1,201,665
- YE Surplus: \$103,898
- Net Worth: \$1,005,398
- Reserve: \$467,483.28

2022 YE

- Total Income: \$1,601,897
- Total Expense: \$1,555,628
- YE Surplus: \$46,269
- Net Worth: \$1,166.014
- Reserve: \$415,363.07

• 2023 YTD

- *Budgeted* Income: \$1,693,356
- *Budgeted* Expense: \$1,660,212
- Budgeted YE Surplus: \$33,144
- 7/31 Income: 79.52%
- 7/31 Expense: 57.34%
- 7/31 Net Worth: \$1,322,217
- 7/31 Reserve: \$558,692.76

No media campaign funds are represented here. The media campaign is accounted for separately.

Membership



Compounding the Joy of Living

2021 YE

Individual Ph: 661

Individual Tech: 191

• Individual Supporter: 78

• Students: 114

• Total Members: 1,044

• 2022 YE

• PFM Members: 3,223

• Individual Ph: 372

• Individual Tech: 35

• Individual Supporter: 34

• Prescribers: 11

• Students: 26

• Total Members: 3,701

• PFM Companies: 100



• 2023 YTD

• PFM Members: 3,723

Individual Ph: 341

• Individual Tech: 29

• Individual Supporter: 35

Prescribers: 9

• Students: 26

Total Members: 4,163

PFM Companies: 125



Thank you, Fagron!

FOR SPONSORSHIP OF APC-BRANDED YETI MUGS FOR PHARMACY/FACILITY MEMBERS



Defending the Profession

Legal:

- APC to file amicus briefs in 4 Novo Nordisk lawsuits against compounders
- Funded by APC's Legal Action Fund (current LAF balance: ~\$67k)
- Attorney: Mark Boesen, Boesen & Snow, Scottsdale, Ariz.
- Our interest: Preserving the ability of pharmacy compounders to prepare copies of FDA-approved drugs when those drugs appear as "currently in shortage" on FDA's shortage list





Defending the Profession

Advocacy:

- California
 - Via APC's Legal Action Fund, a group of California compounders is seeking to influence the CA General Assembly's upcoming reauthorization of the CA BOP.
 - For details: Peter Koshland or Erin Michael
- Compounding the Joy of Living / cBHT Campaign
 - Fundraising is flat
 - Focus on Geo-Fencing and the PBS video
 - 2024?
 - "Demonstrably difficult" rule?
 - Engaging prescribers
 - Compounding the Joy ...

The compounded hormones that cleared your brain fog?

Your access may soon be restricted

JOIN THE FIGHT



Year 3: Total Campaign Results as of 2023 (reduced media budget)

40,167,888 **Americans Reached** + 62.79% increase to 2022 Website Pageviews 499,640 + 73.36% (new home, patient and congress pages) increase to 2022 5,157 **Testimonials Submitted** + 17.58% increase to 2022 **Congressional Offices** 1,429 + 194.03% Reached increase to 2022 5,388 Senders to Congress +41.98% increase to 2022



Purchasing Power

- New APC credit card processing deal with WorldPay
- Participation available only to PFM members
- The Processing Brokerage: customer service and onboarding
- Currently with WorldPay? You'll have to wait ...
- 2022 survey: On average, PFMs were paying 28¢ per transaction
- Our deal starts at 11.5¢ for all participants ... and that per-swipe fee will go down as volume and number of pharmacies in the GPO grows.
- Note that some pharmacy software vendors already have a financial deal with particular credit card processors and these pharmacies will not be able to join APC GPO unless they change software or use a standalone credit card processing setup that does not connect with software

APC PRICING							
# of Merchants		# of Transactions		Volume in \$		Proposed Pricing	
Lower Band	Upper Band	Lower Band	Upper Band	Lower Band	Upper Band	bps	per tran
0	5	0	180,000	\$0	\$18,000,000	0.011%	\$0.011
6	25	180,001	900,000	\$18,000,010	\$90,000,000	0.0975%	\$0.0975
26	50	900,001	1,800,000	\$90,000,100	#########	0.080%	\$0.080
51	100	1,800,001	3,600,000	#########	#########	0.070%	\$0.070
101	150	3,600,001	5,400,000	#########	#########	0.065%	\$0.065
151	200	5,400,001	7,200,000	#########	#########	0.060%	\$0.060
201	250	7,200,001	9,000,000	#########	#########	0.050%	\$0.050

Knowledge & Ethics



The first step to truly helping your patients regain or maintain their health is not your depth of understanding of chemistry or pharmaceuticals or compounding. **It's trust**. We earn that trust through our actions, by consistently operating our pharmacies to the highest ethical, legal, and regulatory standards. Every day. With every prescription we fill.

The Ethical, Legal, and Regulatory Foundations of Pharmacy Compounding

A 15-hour foundational curriculum aimed at equipping you to earn your patients' trust.



Earning their trust takes more than your technical expertise. It's equally important that patients know that you and your teammates have an essential understanding of the laws, regulations, and policies that govern pharmacy compounding. That you operate in compliance with those rules. It's critical for compounding well.

But you can't comply with rules and regulations that you don't know.

Taught by experienced professionals.

The faculty teaching this program have, collectively, decades of hands-on experience in compounding pharmacy and patient care. You will be learning from the best in the business.

Take the course. Earn their trust. Build your business.

Online. Affordable.

This is an online CE course, allowing you to complete the certificate at your own pace. It's also priced well below most CE courses. Every pharmacist and pharmacy technician involved in compounding should earn this essential certificate. Because it's that important.


PHARMACISTS/PHARMACY TECHNICIANS......\$495/ea

PHARMACISTS/PARMACY TECHNICIANS EMPLOYED
BY AN APC PHARMACY/FACILITY MEMBER......\$395/ea





Risk Management + Legal Protection



- PFMs get FREE membership in AMPS, a patient safety organization, but only about 40% of PFMs have registered.
- Why you should register:
 - Compliance: Meets state BOP requirement that you have an active QA program
 - **Legal Protection:** Your pharmacy data collected within the PSO for patient safety improvement analysis is privileged and can be protected from discovery
 - **Resources:** Medication safety experts are available for data analysis and consultation, including guidance when conducting root-cause analysis
- Visit Tara at her table here at CCH





State Influence 2023

- 12 states: AL, CA, DE, ME, MS, MT, NC, NY, OR, TN
- 16 comment letters [SEP]
- 3 memos to all BOPs: USP 797, GFI 256, DTE
- 2 calls to action



Advising Prescribers

Prescriber Briefings: For APC members only

Use these to educate prescribers you work with about what compounders can (and cannot) do

The Truth About Pharmacy Compounding

A briefing for physicians and other prescribers

A highly regulated profession

considing to me a new piercom enon. It goes back a thousand years or more, to the very negonings of pharmery practice. in an amount world in which standardized man-produced drugs are not yet drammet of compounding was pharmed - missing ingrellwith 40-country a common for a specific period. Prior the sizeole addition of green flavoring

Pharmiscy practice has rome a long way critical medications in shortage, compounding since Gwn, and so has plasmacy compounding plasmacon are highly regulated, affecting to Wiser has remained consistent in the role migh standards of quality, and compliance has of compounding in besithoure. These days, as with phermaconical manufacturers, the upon an order from a prescriber, traditional acres phermaconical impedients — AFT compounding pharmacies are pure ingresions. That compounding pharmacies use most comin count contemized medications for a specific. from EDA-registered facilities and manufachumanum - al curione.

Plannacy compounding by homes patients, them me subject to exacting regulation and me tion. Is a legary therapy that existed well before. Impected by saine bounds of pharmacy and by the establishment of pages produced drags the FDA to addition, pharmacy compounders and government regulation of those drops itni must adhere to state lows and regulations fishing a legacy stock-net mean the obsolete or governing compounding as well as standards erant: in fact, the American localiticare communicated by the United States, Pharmasystem depends on pharmicy compounding, especia, the internationally recognized stan-Compounding 16 as appropriate and expert- danks-setting proprietation in fact many 19 tid therapy option where, is the julgement of a - por all) states have expressly adopted some prescriber, in FDA-approved mass-positions or all USF standards directly important truedring is not suited to a specific huntar patient's med. This is who it is employeed to the U.S. Food. The they and health of millions of Americans are





but a physicism of other prescriber:

ice a child's medication to the compounding o

more. Commending labs and the equipment in

FDA's GFI #256 on Animal Compounding Veterinarians must note medical rationale on prescription

Medicine's Guidance for Industry 250, effective April 1, 2023, veterinarians must nescribing certain communited modi-ation such as compounded drugs prepared from pure imgradients that FDA considers similar commercially available manufactured drugs. When orquested by your pharmacy to you'de job; information, one of the following. rationale may be provided:

Commercial product would reduce compliance and/or is not effective for achieving medical outcome.

- Multiple tablets/magnules or hijd-volume ML preded to dom mimil
- tention! durange from: Medications control be aptit appropriately.
- Creaming of June is unarrise-vehicle; nertial product is not available

- Examples:
- Osserdigant reality available commercials



Pharmacy Compounding Foundation

Utilization of commercially available dosage form is unachievable or unsafe for patient.

Green from a cosmed donage from

Patient and/or population has an

intolerance, sensitivity, toxicity, or aversion to commercial product.

noute, conical professed.

Loction intulerince

· Xylind muteley

INTER ARRADY NAME.

Sharp bears

Compounding Peptides: It's Complicated A briefing for physicians and other prescribers

Composition charmecies frequently get loost requests from prencibers to compound a medication that is probibited under Section 503A of the Pederal Food, Drug & Commetic Act. When a compounding of armacist must lectine to IIII a prescription for a particular compounded medication, that's usually the

many of which were reclassified in March | ne compas 2020 by fedirent low as biologica Traditional Under federal law (Section 50 sA), to be eligible ingredient must meet one of the following motific Semeglatide is the active ingredien

- t. Be-an active ingredient in an FDA suppresent drug product.
- 2. Have a USP or flational Formulary drug monograph.
- Enterim or Final Builty List. published by FDA.

A current "hot" analyst in the anti-ering. March 2020 law reclassified both texamorelle and brogrative medicine world is peptides. and BCG as biologics, so they may no longer

rempe ling pharmation cannot compound because of their smaller molecule size sources that are classified as biologics (specifically, 50 amino 4500 as fewer), do-In addition, most peptides do not meet any of the meet the definition of a biologic, set do we other legal requirements for compounding order one of the three legal criteria for use in remponding the is senagitable Other or use in a compounded product, an active include, for example, sermorelin and bremelin an FDA-approved drug product.

The issue is complicated to the fact that a drug manufacturer now markets an FDA-quproved semisdatide repidant, which may be protected by U.S. patents: Thus, compounding mind semarbitide APL depending on the copy" of an FDA -approved-drug, and therefore As a result, most peoples are off limits for FDA approved senselutide product has free raditional compounding, as they are either on the FDA Drug Shortage List since March of classified as biologics or don't meet now of 2022, which may render it permisable for use





Compounding for Racehorses

An overview for veterinarians

approximed by veterinarians to prepare madications for raciltomes. As a tightly rules and regulations regarding the use of drugs in botses. The new anti-doping and medication control program learning by () Hornessian Integrity and Safety Authoray (IIII5A) on Mainth 27, 2023, addresses the use of burumit and non-apparent substances in harmouring litmrever, it is important to

Compounding and the HISA ADMC Program

Visuler (for HISA ADMC traverage, Bulle Art E. ho, titled "non-approved substances," state than communitied products that comply with the Asimal Medicinal Drug Use Clarification Act (AMDUCA) and the FDA Guidance for Industry (GET) #256 (Compounding Anima) Drugs from Bulk Drug Substances) are not prohibited, it is important for veterinarians to understand that they can continue to rely on compounding pharmacles to provide medications for their care burses.

Doring a March 2023 phone conversa with APC staff, the biorserocing Integrity



under the new HISA ADMC program. Buleproducts that comply with AMDUCA and fift

Mary Scollay, emphasized the importance of

horse's specific needs. This is particularly

basse is unlinee and may require a different

important in horseracing, where well

countied medications in the boneracing

Compounding pharmacies pasy a critical vote in providing contomized medications for carefuses that meet their specific needs. As A reperimentan, it is immertant to implement rely on treated compounding pharmacles to provide safe and effective medications for

Prescription Compliance: DEA's "Wet Signature" Requirement

A briefing for physicians and other prescribers

Physicians and other prescribers know they | characters must manually sign paper prescriptions for controlled substances, including prescriptions contrated by commuter or a respectively applicacation that are then printed or faxed. However, a great deal of confusion and misinformation exists about how the Drug Enforcement Agen cy's (DEA) "wet alguaniere" requirement applie to electronic prescriptions for controlled sub STANCES ("EDUS").

mucists may mistakenly believe that secure-sig- require two-factor authentication, not hast a nature solutions like DocuSign comply with this requirement. Determining whether an applicaunderstanding of the EPCS rules and Divusion's

The DEA's "wet signature" rules for EPCS. the Code of Federal Regulations ("CFR"): 21 CFR designed to ensure that prescribers of controlled

secure signature.

21 CFR & 1111 120(b)(4) provides as follows The electronic apparentials medication mass the employments of 5 cars are only proming ations and for anasosino date that sar restricted and armine metrolled substance








A4pc.org/prescriberbriefings

2023 Snapshot of Pharmacy Compounding

- 2023 survey of 15,000+ compounders launches next month
- Partnership between APC and University of Utah College of Pharmacy
- Support from Fagron, Medisca, PCCA
- By year-end: 2023 Snapshot, a demographic profile of the pharmacy compounding industry




Mitigating Regulatory Risk with DATA

What's in FDA's "Demonstrably Difficult" Rule?

- New criteria and new drug products adopted at same time?!
- But this should be a two-step process ...
- The threat to compounded hormones?

Standardized Data Collection: Patient Reported Outcomes





Why OutcomeMD?

- Pharmacy Compounding Foundation
- Validated measures: Same as FDA requires in NDA process
- Consistency: Ability to aggregate across pharmacies
- Coming soon: PCF-funded workflow/integration fixes what will make the process more turn-key
- FDA's demonstrably difficult rule and what may follow it: Time is short.

Keep up. Fridays in your email box.





Alliance for Pharmacy Compounding

Compounding the Joy of Living





App Schedules and Logistics Overview





Senator Ben Ray Luján

New Mexico 5:15p Reception • \$1,000



Cong. Richard Hudson

North Carolina 6:30p Dinner • \$1,000



Cong. Diana DeGette


Colorado 7:50a tomorrow












Ashley Berthelot

Professional Arts Pharmacy Lafayette, Louisiana









Amy Shank

PCCA Director of Government Relations



David Pore

APC Governmental Affairs Counsel







Amy Shank

PCCA Director of Government Relations



David Pore

APC Governmental Affairs Counsel





Amy & David slides here







What we'll discuss

- Compounded hormones
- Drug shortages & supply chain
- Coming attractions
- What's in your packets





The Threat to Compounded Hormones

- NASEM report
- Compounding.com
- Senate ask: Add your name to a letter to FDA led by Senators Baldwin (WI) and Marshall (KS)
- House ask: Contact the FDA to express concern about bias and lack of scientific rigor in the FDA-funded NASEM cBHT report. Forward the July 2023 House letter to the FDA with an expression of your support.





A Fix for Drug Shortage and Supply Chain Issues

- HR 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023, sponsored by Rep. Morgan Griffith (R-VA) and Henry Cuellar (D-TX), creates a permanent path for 503A pharmacies to provide urgent use and shortage drugs to hospitals and physicians when those drugs cannot be sourced from the manufacturer or a 503B outsourcing facility
- House ask: Call the Energy & Commerce committee and ask that they include HR 167's provisions in any drug shortage or pandemic preparedness package
- Senate ask: Introduce a Senate companion bill to HR 167. Please sponsor an effort to include HR 167's provisions in any drug shortage or pandemic preparedness package.





Energy & Commerce Committee Members

- Cathy McMorris Rodgers,Washington
- Michael C. Burgess, Texas
- •Bob Latta, Ohio
- •Brett Guthrie, Kentucky
- Morgan Griffith, Virginia
- •Gus Bilirakis, Florida
- •Bill Johnson, Ohio
- •Larry Bucshon, Indiana
- •Richard Hudson, North Carolina
- •Tim Walberg, Michigan
- •<u>Buddy Carter</u>, Georgia
- •<u>Jeff Duncan</u>, South Carolina
- Gary Palmer, Alabama
- •Neal Dunn, Florida
- •John Curtis, Utah

- •Debbie Lesko, Arizona
- Greg Pence, Indiana
- •<u>Dan Crenshaw</u>, Texas
- •John Joyce, Pennsylvania
- •Kelly Armstrong, North Dakota
- •Randy Weber, Texas
- •Rick Allen, Georgia
- •<u>Troy Balderson</u>, Ohio
- •Russ Fulcher, Idaho
- August Pfluger, Texas
- •Diana Harshbarger, Tennessee
- •Mariannette Miller-Meeks, Iowa
- •Kat Cammack, Florida
- •Jay Obernolte, California
- •<u>Frank Pallone</u>, New Jersey
- •Anna Eshoo, California
- •<u>Diana DeGette</u>, Colorado
- •Jan Schakowsky, Illinois

- Doris Matsui, California
- •Kathy Castor, Florida
- •John Sarbanes, Maryland
- •Paul Tonko, New York
- •<u>Yvette Clarke</u>, New York
- •Tony Cárdenas, California
- •Raul Ruiz, California
- •Scott Peters, California
- •<u>Debbie Dingell</u>, Michigan
- Marc Veasey, Texas
- •Annie Kuster, New Hampshire
- •Robin Kelly, Illinois
- •Nanette Barragán, California
- •Lisa Blunt Rochester, Delaware
- •<u>Darren Soto</u>, Florida
- Angie Craig, Minnesota
- •Kim Schrier, Washington
- •Lori Trahan, Massachusetts
- •Lizzie Fletcher, Texas





A look ahead

PHARMACY COMPOUNDING REPORTING ACT OF 2023

- 1. It would repeal a 1997 MOU requirement in the Food, Drug & Cosmetic Act and the burden of FDA having to cajole states sign an MOU and replace it with a requirement for reporting to state boards of pharmacy by all traditional compounding pharmacies that ship more than 50 percent of their compounded drugs out-of-state. This goes well beyond the reporting required under the 1997 MOU directive, to include reporting on compounded drugs dispensed pursuant to a patient specific prescription.
- 2. It would create a framework for mandatory reporting of serious adverse events by traditional compounding pharmacies a requirement long sought by FDA.





In your leave-behind packet for members:

- Summary of Asks
- 3 issue one-pagers
- A comparison doc on HR 167
- STAT opinion piece on compounding and drug shortages
- Senate hormone letter (currently open)
- House hormone letter (just submitted in 2023)
- Snapshot of pharmacy compounding (2021)













Laura Bray

Founder, Angels for Change



Philip Smyth

Director of Global Public Affairs, Medisca









Senator Ben Ray Luján

New Mexico 5:15p Reception • \$1,000



Cong. Richard Hudson

North Carolina 6:30p Dinner • \$1,000



Cong. Diana DeGette

Colorado 7:50a tomorrow








END OF DAY 1





Ashley Berthelot

Professional Arts Pharmacy Lafayette, Louisiana








Onyx Ahmad

Technical Sales & Quality Manager
International Filter Products







International Filter Products







Putting customers first, always!

- Instant Shipping from \$2.5M Inventory.
- Effortless Ecommerce Experience.
- Inquiry Response in 24ours.
- Consult Engineers for Tech Support.
- Data for Volume Range & Optimal Sizing.
- Plus: Exclusive Complimentary Services.

(Call or Email to Discover More)





Team Experience

Engineering

50+ Years of

Combined

Experience.

Technical Sales

- Comprised of Engineers.
- Dedicated East Coast Representative Available.

Shipping & Handling

Adheres to ISO


9001:2015 for

Flawless Execution.






Order Processing Error







Customer Inquiries & Orders Acknowledged On-Time







Strengthening the compounding community with

the Alliance for Pharmacy Compounding.



Bonus

Bubble Point Test

Detailed Guide Available.


Please Visit Our Booth



















Please welcome

Lucy Malmberg













Sue Horton, RPH

Central Iowa Compounding Pharmacy Urbandale Iowa

2023 George and Lucy Malmberg Compounding Advocacy Champion





If I Can Do It, So Can You.

Ashley Berthelot

Professional Arts Pharmacy Lafayette, Louisiana











act of congress



THAT WHICH IS EXTREMELY DIFFICULT TO ACHIEVE OR REQUIRES A LARGE AMOUNT OF EFFORT OR PATIENCE TO FNACT PRIMARILY HEARD

Before Your Meeting




Research the Congressional member

• Prep work is VERY important to a successful outcome!

 Read their bio and have a general understanding of their viewpoints, status, influence, etc. (In the Uber / Hallway)

 Read through previous year's notes to build on your relationship. Pick up where you left off.

Before Your Meeting



Prepare for Political Pitfalls.

Expanded vs Limited Government

 Recognize that different parties have varying views on many issues, such as government agency involvement.

Hormones – *New* Sensitive Issue

 You may have to explain that compounding pharmacists can and do provide hormones for transitioning individuals, though the vast majority of compounded hormone therapy is replacement for individuals going through menopause and andropause.

Reframe to non-partisan patient access!

Before Your Meeting

Memorize as much as possible about "the asks"

- Figure out how to simplify the message
- Asks may be summed up by "Patient Access" barriers

Correlate the asks to your business and explain the impact

- Impact could be:
- Patients
- Physicians
- You



Be prepared to show up as YOU

- Constituent
- Business owner
- Patient
- Person with needs

from the State/District

During Your Meeting

Your meeting time should have three distinct parts:

3. Wrap up

2. Issue discussion

1. Setting up the conversation & relationship

Setting Up the Convo & Relationship









Setting Up the Convo & Relationship Ask questions!!!! (SALES 101)

• DO NOT show up and throw up!

You ARE selling a story!

 Is your story compelling enough for them to BUY? (aka: DO AN ACTION)

Setting Up the Convo & Relationship

ASK...

if they understand what compounding is.

Give a relatable explanation.
I use baking cookies vs buying chips ahoy off the grocery store shelf.

ASK...

if they or anyone close to them has ever used a compounded medication before,

or needed a medication problem solved.

THEN...

tell them what you do.


Fill in their gaps and have a patient story or two teed up.

Issue Discussion

- Have a common language conversation.
- Leave the lawyer sounding, bill language to the leave behinds, white papers, or your APC representative.
- You are there to tell a story and ask for help.

"We are here to talk to you today about some issues that we are having that really affect our pharmacy, our patients, and our doctors, and we'd like your help. It basically boils down to access issues that affect patient safety and ability to receive needed medications."





Wrap Up

ehind eav

Pharmacy folder or marketing material


Business card for contact information

OFFER: (1) to be a district <u>resource</u> and (2) a <u>tour of your pharmacy</u>

Formal information on items discussed in PCCA folder

Offer APC's support for any specifics on current legislation

Wrap Up




Do they understood what you are asking of them?

 ASK where they think the member would stand on these issues

"What do you think the level of support or commitment could be? What type of follow up would you like? How can we help you help us?"

Wrap Up

- Thank them again for their time.
- Grab a business card for everyone that was present in your meeting.
- Write notes on the backs of all cards.




After Your Meeting

- Send a personal thank you note card.
 - This can also be done via email, especially highlighting the points you reviewed.
- Be prompt to send any follow up homework requested by the member or their staff!









Scott Brunner, cae









Congresswoman Diana DeGette

Colorado





